As of today (2024-04-23), ADMA Biologics's share price is $6.53.
ADMA Biologics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.02. Hence, ADMA Biologics's Price-to-Free-Cash-Flow Ratio for today is 408.13.
The historical rank and industry rank for ADMA Biologics's Price-to-Free-Cash-Flow or its related term are showing as below:
ADMA'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 275 Med: 345 Max: 412.5
Current: 385.13
During the past 13 years, ADMA Biologics's highest Price-to-Free-Cash-Flow Ratio was 412.50. The lowest was 275.00. And the median was 345.00.
ADMA's Price-to-Free-Cash-Flow is ranked worse than 92.45% of 212
companies
in the Biotechnology industry
Industry Median: 30.29
vs ADMA: 385.13
During the past 13 years, ADMA Biologics's highest 3-Year average Free Cash Flow per Share Growth Rate was 36.80% per year. The lowest was -496.40% per year. And the median was 1.35% per year.
ADMA Biologics Price-to-Free-Cash-Flow Historical Data
The historical data trend for ADMA Biologics's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ADMA Biologics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Price-to-Free-Cash-Flow Distribution
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Price-to-Free-Cash-Flow falls into.
ADMA Biologics's Share Price of today is $6.53.
ADMA Biologics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
ADMA Biologics Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of ADMA Biologics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
ADMA Biologics (ADMA Biologics) Business Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADMA has been successfully added to your 